(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 39.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.8%.
Sangamo Therapeutics's revenue in 2023 is $111,299,000.On average, 5 Wall Street analysts forecast SGMO's revenue for 2023 to be $22,582,829,877, with the lowest SGMO revenue forecast at $15,146,650,198, and the highest SGMO revenue forecast at $42,205,070,909. On average, 4 Wall Street analysts forecast SGMO's revenue for 2024 to be $28,550,677,449, with the lowest SGMO revenue forecast at $12,102,156,660, and the highest SGMO revenue forecast at $38,784,859,573.
In 2025, SGMO is forecast to generate $54,112,123,888 in revenue, with the lowest revenue forecast at $13,729,705,502 and the highest revenue forecast at $90,492,389,561.